US biotech RaNA Therapeutics has announced the acquisition of the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire (LSE: SHP).
Under the terms of the agreement, Shire receives an unspecified equity stake in RaNA and is eligible for future milestones and royalties on products developed with the technology. Further financial terms were not disclosed.
The former MRT employees from the Ireland-incorporated drugmaker, the group focused on the development of this technology since 2008, have joined RaNA to continue to advance the platform with lead programs in cystic fibrosis (CF) and urea cycle disorders (UCD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze